# 2026-20448: FDA Frees Drug Test Kits from Premarket Paperwork Hassle

2026-20448, Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-10-06; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20448
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20448
- Title: Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63478
- Published: 2026-10-06
- Effective: 2026-10-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

FDA Frees Drug Test Kits from Premarket Paperwork Hassle

## Summary

Starting October 6, 2026, the FDA is letting certain clinical toxicology test systems skip the usual premarket approval step, cutting red tape and saving money for medical device makers. This change means these devices can get to market faster without extra paperwork, helping labs and patients get quicker results. If you make or sell these test systems, this update is a big win for your business and the healthcare world!

## Abstract

The Food and Drug Administration (FDA) is publishing an order setting forth its final determination to exempt certain class II clinical toxicology test systems from premarket notification (510(k)) requirements, subject to certain limitations. This exemption from 510(k) requirements, subject to certain limitations, is immediately in effect for such devices. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations. FDA is amending the classification language within the Code of Federal Regulations (CFR) for certain class II clinical toxicology test systems to reflect this final determination. FDA is publishing this order in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).

## Effects PRIA read

- 510(k) Exemption Expanded to Federal Programs: benefit, high. Starting October 6, 2026, FDA is expanding 510(k) premarket notification exemptions for certain class II clinical toxicology test systems to include devices intended for use in Federal drug testing programs. The rule amends several CFR classification sections (for example, 21 CFR 862.3100, 862.3150…
- Labeling Limit: Employment & Insurance Use Only: cost, low. The exemptions apply only to test systems that are intended for employment and insurance testing and whose labeling includes a statement that the device is intended solely for employment and insurance testing. If a device's intended use or labeling does not meet this partial limitation, a 510(k) su…
- Other Regulatory Requirements Still Apply: cost, medium. Even when exempt from 510(k), these clinical toxicology test systems remain subject to other FDA and statutory requirements such as establishment registration, device listing, quality system (21 CFR part 820) requirements, labeling rules, and medical device reporting. If used in Federal drug testin…
- Product Code Reassignments for Exempt Devices: benefit, low. Devices that become 510(k) exempt will shift from their prior non-exempt product codes to corresponding exempt product codes (the rule notes examples and that definitions for exempt product codes will be updated). For example, certain fentanyl test systems previously listed under product code DJG w…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20448 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20448/medical-devices-exemptions-from-premarket-notification-class-ii-devices-certain-clinical-toxicology)
- [2026-20448 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20448.pdf)

## Related
- [Previous: 2026-20447, Transparency in Coverage](https://policyrisk.com/federal-register/2026-20447)
- [Next: 2026-20461, Adoption of Updated EDGAR Filer Manual](https://policyrisk.com/federal-register/2026-20461)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20448 (as of 2026-10-13).
